Psychedelics.media today announced the official launch of its global business to business media platform dedicated to psychedelic medicine, mental health innovation, neuroscience and emerging healthcare technologies.
Created to serve psychiatrists, psychologists, physicians, nurses, researchers, academics, healthcare providers, biotechnology companies, policymakers, investors and industry executives, Psychedelics.media aims to provide trusted journalism, industry intelligence and professional engagement opportunities for one of the fastest-growing sectors in modern healthcare.
The launch comes as psychedelic medicine continues to gain momentum internationally, driven by increasing clinical research, expanding regulatory discussions, growing investment activity and rising interest in novel treatments for mental health conditions including depression, PTSD, anxiety and addiction.
Psychedelics.media will provide daily coverage of scientific research, clinical developments, healthcare implementation, public policy, regulation, biotechnology, drug development, cultivation, manufacturing, investment activity and emerging commercial opportunities across the psychedelic sector.
In addition to reporting on research and healthcare developments, the publication will provide ongoing coverage of publicly listed companies, private biotechnology firms, capital markets activity, funding rounds, mergers and acquisitions and the broader business landscape shaping the future of psychedelic medicine worldwide.
While the platform will maintain a global editorial focus, it also aims to increase visibility for developments occurring throughout Australia, New Zealand, Asia-Pacific, United Kingdom, Thailand and other regions that have historically received less industry media attention than North America and Europe.
Beyond its online news platform, Psychedelics.media publishes a professionally produced bi-monthly digital magazine featuring long-form journalism, executive interviews, market analysis, clinical insights and thought leadership from leading voices across healthcare, academia and industry.
The publication’s second edition is scheduled for release end June 2026.
“Having spent nearly a decade helping pioneer the medicinal cannabis industry in Australia and working across international markets including Thailand and the United Kingdom, I’ve seen firsthand how quickly emerging healthcare sectors can evolve,” said Gary Mackenzie, Editor of Psychedelics.media.
“Psychedelic medicine is now approaching a similar moment.
Researchers, clinicians, companies and investors are building an entirely new ecosystem around treatments that have the potential to transform mental healthcare. Yet the industry remains highly fragmented, with important developments taking place across multiple countries and disciplines every day.
Psychedelics.media was created to help bring those conversations together.
Our mission is to keep healthcare professionals, researchers, industry executives and investors informed about the people, companies, research and developments shaping the future of psychedelic medicine, while providing a platform for leaders throughout the sector to share their work and perspectives with a global audience.
From clinical trial results and regulatory developments to company announcements, capital raises, healthcare innovation and emerging technologies, our goal is to help the industry stay informed, connected and engaged.”
As part of its industry engagement strategy, Psychedelics.media also announced the launch of the PRS27 Psychedelic Roundtable Symposium, scheduled for 20 March 2027 in Melbourne Australia. Early bird tickets will go on sale mid June.
The event will bring together psychiatrists, psychologists, physicians, nurses, researchers, academics, policymakers, healthcare providers, biotechnology companies, investors, cultivators and industry executives for multidisciplinary discussions on the future of psychedelic medicine.
Topics will include clinical implementation, patient access, research developments, regulation, manufacturing standards, investment, ethics, healthcare integration and the evolving commercial landscape of the psychedelic sector.
Together, the publication, digital magazine and symposium platform aim to support greater collaboration, transparency and knowledge sharing throughout the global psychedelic ecosystem.
As psychedelic medicine continues its transition into mainstream healthcare, Psychedelics.media aims to become a trusted source of news, analysis and professional engagement for the individuals and organisations helping shape the industry’s future.
